Trial Profile
A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2019 Results of phase II part of this study (n=38) published in the Targeted Oncology.
- 09 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.